Trial Evaluating Tiragolumab Combo in PD-L1 High NSCLC Misses PFS Endpoint
A phase 3 trial evaluating tiragolumab in combination with atezolizumab (Tecentriq®) in adults with PD-L1 high locally advanced or metastatic non-small cell lung cancer (NSCLC) did not meet its coprimary endpoint of progression-free survival (PFS),…